表紙
市場調査レポート

Vaxeal Holding SAの製品パイプライン分析

Vaxeal Holding SA - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256041
出版日 ページ情報 英文 18 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
Vaxeal Holding SAの製品パイプライン分析 Vaxeal Holding SA - Product Pipeline Review - 2015
出版日: 2015年12月30日 ページ情報: 英文 18 Pages
概要

Vaxeal Holding SAは、スイスに本社を置く製薬企業であり、癌や感染症に対し免疫調節薬を併用した治療ワクチンの開発を行っています。

当レポートでは、Vaxeal Holding SAにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Vaxeal Holding SAの基本情報

  • Vaxeal Holding SAの概要
  • 主要情報
  • 企業情報

Vaxeal Holding SA:R&Dの概要

  • 主な治療範囲

Vaxeal Holding SA:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Vaxeal Holding SA:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Vaxeal Holding SA:薬剤プロファイル

  • MDX-1 Vaccine
  • SVX-1 Vaccine
  • Vaccine For Hepatitis C
  • Cancer Combination Vaccine
  • CBX-1 Vaccine

Vaxeal Holding SA:パイプライン分析

  • 標的別
  • 分子タイプ別

Vaxeal Holding SA:開発休止中のプロジェクト

Vaxeal Holding SA:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07936CDB

Summary

Global Markets Direct's, 'Vaxeal Holding SA - Product Pipeline Review - 2015', provides an overview of the Vaxeal Holding SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vaxeal Holding SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vaxeal Holding SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vaxeal Holding SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vaxeal Holding SA's pipeline products

Reasons to buy

  • Evaluate Vaxeal Holding SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vaxeal Holding SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vaxeal Holding SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vaxeal Holding SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vaxeal Holding SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vaxeal Holding SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vaxeal Holding SA Snapshot
    • Vaxeal Holding SA Overview
    • Key Information
    • Key Facts
  • Vaxeal Holding SA - Research and Development Overview
    • Key Therapeutic Areas
  • Vaxeal Holding SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Vaxeal Holding SA - Pipeline Products Glance
    • Vaxeal Holding SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Vaxeal Holding SA - Drug Profiles
    • CBX-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SVX-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vaxeal Holding SA - Pipeline Analysis
  • Vaxeal Holding SA - Pipeline Products by Molecule Type
  • Vaxeal Holding SA - Dormant Projects
  • Vaxeal Holding SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vaxeal Holding SA, Key Information
  • Vaxeal Holding SA, Key Facts
  • Vaxeal Holding SA - Pipeline by Indication, 2015
  • Vaxeal Holding SA - Pipeline by Stage of Development, 2015
  • Vaxeal Holding SA - Monotherapy Products in Pipeline, 2015
  • Vaxeal Holding SA - Preclinical, 2015
  • Vaxeal Holding SA - Discovery, 2015
  • Vaxeal Holding SA - Pipeline by Molecule Type, 2015
  • Vaxeal Holding SA - Dormant Developmental Projects,2015
  • Vaxeal Holding SA, Subsidiaries

List of Figures

  • Vaxeal Holding SA - Pipeline by Top 10 Indication, 2015
  • Vaxeal Holding SA - Pipeline by Stage of Development, 2015
  • Vaxeal Holding SA - Monotherapy Products in Pipeline, 2015
  • Vaxeal Holding SA - Pipeline by Top 10 Molecule Type, 2015
Back to Top